Auvelity's Alzheimer's Launch Is Growing, but Investors Wanted More

Axsome Therapeutics' first full quarter selling Auvelity for agitation associated with Alzheimer's disease produced rapid prescription growth, but investors wanted an even faster start. The stock fell sharply after the third-quarter report as analysts lowered forecasts while keeping generally positive ratings.

Auvelity generated $207.6 million of net product sales in the quarter, up 53% from a year earlier. Across both approved uses, major depressive disorder and Alzheimer's agitation, the company reported about 302,000 prescriptions. Total prescriptions rose 14% from the second quarter, while new-to-brand prescriptions, which track new patient starts, rose 21%.

The older-patient data give the launch more context. Among patients aged 65 and above, new-to-brand prescriptions increased 99% from the second quarter and 211% from a year earlier. Total prescriptions in that age group rose 43% sequentially and 101% year over year. Axsome also said Auvelity had payer coverage for about 89% of covered lives, including full coverage in government channels on its measure.

Those figures show adoption, but they do not disclose how much of Auvelity's quarterly revenue came specifically from the Alzheimer's indication. That missing split helps explain why investors and analysts can reach different conclusions about launch speed. A fast percentage increase from an early base can coexist with revenue below aggressive forecasts.

The analyst response was mixed rather than uniformly negative. According to Stocktwits, Jefferies cut its price target to $305 from $380 and trimmed its 2026 and 2027 Auvelity forecasts, while still citing strong new-to-brand prescription trends. Piper Sandler reduced its target slightly to $235 and lowered Symbravo estimates, but described Auvelity volume as evidence of encouraging early adoption. TD Cowen kept a Buy rating and a $135 target, arguing that launch concerns were overdone. These targets are attributed opinions, not company guidance.

The quarter also showed why launch execution matters so much. Axsome's total net product revenue rose 52% to $259.7 million, yet selling, general and administrative expense climbed to $203.1 million from $150.2 million a year earlier. The net loss narrowed to $12.9 million from $47.2 million, but commercial spending still consumed most of the revenue generated by the lead product.

Management expects new patient starts in Alzheimer's agitation to continue accelerating. Investors should test that claim against the next prescription update, not just target-price revisions. The clearest evidence would be sustained growth among older patients, a larger contribution from the new indication and a continued decline in operating losses. Until Axsome reports indication-specific economics, the launch can reasonably be described as growing quickly without proving that it has met the market's highest expectations.